Evidence from RCTs showed that treatment with IV idursulfase significantly reduced uGAG levels after 12 months of treatment in children and adults with MPS II (range of the change from baseline: −43% to −52.5%, p < 0.0001) [13,19]. The gene discussed is IDS; the disease is mucopolysaccharidosis type 2.